Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Share News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.50
Bid: 52.00
Ask: 55.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.77%)
Open: 53.50
High: 53.50
Low: 53.50
Yest. Close: 53.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Beximco To Distribute Mylan Product Portfolio In Bangladesh

Mon, 24th Feb 2020 12:00

(Alliance News) - Beximco Pharmaceuticals Ltd on Monday said it has signed a commercial agreement with Mylan NV giving it the exclusive right to distribute some Mylan products in Bangladesh.

Beximco is based in Bangladesh and manufactures and exports medicines. Its shares were up 3.3% at 44.62 pence in London in late morning trading.

Beximco will, under the deal between the two generic drug makers, gain "the exclusive rights to launch Mylan's portfolio of key monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Chron's disease, ulcerative colitis and other medical conditions."

Antibodies are normally developed by an organism in response to a foreign invader called an antigen, binding to it. This has many application in medicine. For example, antibodies can be developed which bind to a target antigen and cause the body's immune system to attack cells with that antigen - such as cancer cells.

The first Mylan product in the portfolio to be launched will be breast cancer drug Ogrivi in the first quarter of 2020. This is a biosimilar to Roche Holdings AG's cancer drug Herceptin, which had global sales of more than USD7 billion in 2018.

Orgivi has been approved in the US and has marketing authorisation in the EU. Ogrivi works by binding to a receptor called HER 2 on the cells of some cancers. Beximco noted that cancer is "now one of the leading causes of death in Bangladesh", with "more than 50,000 HER-2 positive breast cancer patients in the country".

Beximco Managing Director Nazmul Hassan said: "We are incredibly excited to announce this commercial agreement with Mylan, the first of its kind in Bangladesh. With one of the largest and most diverse portfolios of biosimilars approved in more than 80 countries, Mylan is the ideal partner for Beximco Pharma as we enter the key therapeutic areas covered by biosimilar products. This unique partnership, which combines world-class product development, marketing and regulatory expertise, will introduce a portfolio of biologics, in particular, target-specific high-value monoclonal antibodies, in Bangladesh. Together, we will be able to provide our patients with more affordable access to these much-needed products."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

UK TRADING UPDATE SUMMARY: Record In Talks For Bumper Hedging Deal

UK TRADING UPDATE SUMMARY: Record In Talks For Bumper Hedging Deal

21 Sep 20 19:29

IN BRIEF: Beximco To Be Exclusive Covid Vaccine Supplier In Bangladesh

IN BRIEF: Beximco To Be Exclusive Covid Vaccine Supplier In Bangladesh

28 Aug 20 14:33

UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends

UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends

30 Jul 20 18:00

UK TRADING UPDATE SUMMARY: Science Group's UK Ventilator Plan Stalls

UK TRADING UPDATE SUMMARY: Science Group's UK Ventilator Plan Stalls

4 May 20 12:10

Beximco To Distribute Mylan Product Portfolio In Bangladesh

Beximco To Distribute Mylan Product Portfolio In Bangladesh

24 Feb 20 12:00

Beximco Pharmaceuticals Earnings Rise Amid Spate Of Product Launches

Beximco Pharmaceuticals Earnings Rise Amid Spate Of Product Launches

29 Jan 20 11:29

Beximco Pharma Reports "Strong" Start To Year As Quarterly Earnings Up

Beximco Pharma Reports "Strong" Start To Year As Quarterly Earnings Up

14 Nov 19 11:14

Beximco Pharmaceuticals Outlook Confident As Earnings Improve In Year

Beximco Pharmaceuticals Outlook Confident As Earnings Improve In Year

11 Nov 19 09:44

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

4 Nov 19 15:58

Beximco gets FDA approval for generic anti-allergy drug

(Sharecast News) - Beximco Pharmaceuticals announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for its cyproheptadine hydrochloride tablet 4mg anti-allergy drug, which is a generic equivalent to 'Periactin' 4mg tablets from Merck and Company.

24 Apr 19 15:41

Beximco adds to US portfolio with purchase of Novartis assets

(Sharecast News) - Generic drugs manufacturer Beximco Pharmaceuticals announced the signing of a definitive agreement with Sandoz - a division of Novartis - to acquire a portfolio of eight 'Abbreviated New Drug Applications' (ANDAs) in the US on Wednesday, for an undisclosed amount in cash.

20 Feb 19 14:46

Monday broker round-up

(Sharecast News) - Sophos Group: Numis upgrades to add with a target price of 580p.

30 Jul 18 13:17

Monday broker round-up

(Sharecast News) - Hargreaves Lansdown: Jefferies downgrades to underperform with a target price of 1,650p.

23 Jul 18 12:53

Beximco profits rise as it begins US exports

(ShareCast News) - Bangladeshi generic pharmaceutical products and active pharmaceutical ingredients manufacturer Beximco Pharmaceuticals announced its unaudited financial results for the six months to 31 December on Friday. The AIM-traded company said net sales increased by 13.6% to BDT 7,630.6m or

27 Jan 17 10:45

Beximco Pharma partners with BioCare in Malaysia

(ShareCast News) - Generic pharmaceutical products manufacturer Beximco Pharmaceuticals announced the creation of a joint venture with BioCare Manufacturing, based in Malaysia, as the company's first overseas manufacturing collaboration on Wednesday. The AIM-traded firm said that under the terms of

25 Jan 17 16:10

Login to your account

Don't have an account? Click here to register.